Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Goodin

Showing results (21-30 of 203) with videos related to

Pageof 21
Sort By:
BMC Neurology|April 28, 2016
The nature of genetic susceptibility to multiple sclerosis: constraining the possibilitiesDouglas S Goodin
Journal of Neurology|November 19, 2004
Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errorsDouglas S Goodin
International MS Journal|January 19, 2006
Treatment of multiple sclerosis with human beta interferonD S Goodin
Neuroepidemiology|February 19, 1999
Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosisD S Goodin
Drugs|November 6, 2001
Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose responseD S Goodin
Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society|March 21, 1998
Cognitive event-related potentialsD S Goodin
Handbook of Clinical Neurology|September 18, 2016
The epidemiology of multiple sclerosis: insights to a causal cascadeD S Goodin
Neurology|December 17, 2008
Disease-modifying therapy in multiple sclerosis: update and clinical implicationsDouglas S Goodin
Lancet (London, England)|June 5, 2003
Interferons in relapsing remitting multiple sclerosisDouglas S Goodin
Neurology|March 1, 1993
Corticosteroids and optic neuritisD S Goodin
Pageof 21

Showing results (21-30 of 203) with videos related to

Sort By:
Pageof 21
BMC Neurology|April 28, 2016
The nature of genetic susceptibility to multiple sclerosis: constraining the possibilitiesDouglas S Goodin
Journal of Neurology|November 19, 2004
Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errorsDouglas S Goodin
International MS Journal|January 19, 2006
Treatment of multiple sclerosis with human beta interferonD S Goodin
Neuroepidemiology|February 19, 1999
Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosisD S Goodin
Drugs|November 6, 2001
Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose responseD S Goodin
Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society|March 21, 1998
Cognitive event-related potentialsD S Goodin
Handbook of Clinical Neurology|September 18, 2016
The epidemiology of multiple sclerosis: insights to a causal cascadeD S Goodin
Neurology|December 17, 2008
Disease-modifying therapy in multiple sclerosis: update and clinical implicationsDouglas S Goodin
Lancet (London, England)|June 5, 2003
Interferons in relapsing remitting multiple sclerosisDouglas S Goodin
Neurology|March 1, 1993
Corticosteroids and optic neuritisD S Goodin
Pageof 21